FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313559631> ?p ?o ?g. }

• W4313559631 abstract "Abstract Background Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of plasma amyloid-beta (Aβ)42/Aβ40 ratio measured by an antibody-free mass-spectrometric (MS) method, ABtest-MS, to detect early pathological changes of AD. Methods This cohort study included data from the baseline and 2-year follow-up visits from the Fundació ACE Healthy Brain Initiative (FACEHBI) study. Plasma Aβ42/Aβ40 was measured with ABtest-MS and compared to 18 F-Florbetaben PET as the reference standard (cutoff for early amyloid deposition of 13.5 centiloids). Cross-validation was performed in an independent DPUK-Korean cohort. Additionally, associations of plasma Aβ42/Aβ40 with episodic memory performance and brain atrophy were assessed. Results The FACEHBI cohort at baseline included 200 healthy individuals with subjective cognitive decline (SCD), of which 36 (18%) were Aβ-PET positive. Plasma Aβ42/Aβ40 levels were significantly lower in Aβ-PET positive individuals (median [interquartile range, IQR], 0.215 [0.203–0.236]) versus Aβ-PET negative subjects (median [IQR], 0.261 [0.244–0.279]) ( P < .001). Plasma Aβ42/Aβ40 was significantly correlated with Aβ-PET levels (rho = −0.390; P < .001) and identified Aβ-PET status with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% confidence interval [CI], 0.80–0.93). A cutoff for the Aβ42/Aβ40 ratio of 0.241 (maximum Youden index) yielded a sensitivity of 86.1% and a specificity of 80.5%. These findings were cross-validated in an independent DPUK-Korean cohort (AUC 0.86 [95% CI 0.77–0.95]). Lower plasma Aβ42/Aβ40 ratio was associated with worse episodic memory performance and increased brain atrophy. Plasma Aβ42/Aβ40 at baseline predicted clinical conversion to mild cognitive impairment and longitudinal changes in amyloid deposition and brain atrophy at 2-year follow-up. Conclusions This study suggests that plasma Aβ42/Aβ40, as determined by this MS-based assay, has potential value as an accurate and cost-effective tool to identify individuals in the earliest stages of AD, supporting its implementation in clinical trials, preventative strategies and clinical practice." @default.
• W4313559631 created "2023-01-06" @default.
• W4313559631 creator A5008503455 @default.
• W4313559631 creator A5011414875 @default.
• W4313559631 creator A5014788787 @default.
• W4313559631 creator A5029554092 @default.
• W4313559631 creator A5031148071 @default.
• W4313559631 creator A5035987097 @default.
• W4313559631 creator A5048460948 @default.
• W4313559631 creator A5050897246 @default.
• W4313559631 creator A5057731725 @default.
• W4313559631 creator A5066499069 @default.
• W4313559631 creator A5068905678 @default.
• W4313559631 creator A5072413175 @default.
• W4313559631 creator A5081007211 @default.
• W4313559631 creator A5082072905 @default.
• W4313559631 creator A5089944976 @default.
• W4313559631 date "2023-01-05" @default.
• W4313559631 modified "2023-10-16" @default.
• W4313559631 title "Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline" @default.
• W4313559631 cites W2112579276 @default.
• W4313559631 cites W2125630263 @default.
• W4313559631 cites W2414917913 @default.
• W4313559631 cites W2596589714 @default.
• W4313559631 cites W2696917520 @default.
• W4313559631 cites W2736518852 @default.
• W4313559631 cites W2750795037 @default.
• W4313559631 cites W2785757836 @default.
• W4313559631 cites W2807443525 @default.
• W4313559631 cites W2883417149 @default.
• W4313559631 cites W2883763513 @default.
• W4313559631 cites W2892024211 @default.
• W4313559631 cites W2900969253 @default.
• W4313559631 cites W2944821536 @default.
• W4313559631 cites W2952677120 @default.
• W4313559631 cites W2966365568 @default.
• W4313559631 cites W2981746313 @default.
• W4313559631 cites W2989446795 @default.
• W4313559631 cites W2990200033 @default.
• W4313559631 cites W2995993939 @default.
• W4313559631 cites W2999941667 @default.
• W4313559631 cites W3009441391 @default.
• W4313559631 cites W3009833354 @default.
• W4313559631 cites W3011286447 @default.
• W4313559631 cites W3012618838 @default.
• W4313559631 cites W3018431352 @default.
• W4313559631 cites W3045997188 @default.
• W4313559631 cites W3047014868 @default.
• W4313559631 cites W3087949202 @default.
• W4313559631 cites W3104533249 @default.
• W4313559631 cites W3123207203 @default.
• W4313559631 cites W3127106548 @default.
• W4313559631 cites W3131174931 @default.
• W4313559631 cites W3143545452 @default.
• W4313559631 cites W3157305846 @default.
• W4313559631 cites W3172300140 @default.
• W4313559631 cites W3174265554 @default.
• W4313559631 cites W3181047500 @default.
• W4313559631 cites W3185118626 @default.
• W4313559631 cites W3186421747 @default.
• W4313559631 cites W3199026337 @default.
• W4313559631 cites W3203425241 @default.
• W4313559631 cites W3206830763 @default.
• W4313559631 cites W3214993261 @default.
• W4313559631 cites W4200169681 @default.
• W4313559631 cites W4205799296 @default.
• W4313559631 cites W4210357094 @default.
• W4313559631 cites W4297036157 @default.
• W4313559631 doi "https://doi.org/10.1186/s13195-022-01143-z" @default.
• W4313559631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36604729" @default.
• W4313559631 hasPublicationYear "2023" @default.
• W4313559631 type Work @default.
• W4313559631 citedByCount "6" @default.
• W4313559631 countsByYear W43135596312023 @default.
• W4313559631 crossrefType "journal-article" @default.
• W4313559631 hasAuthorship W4313559631A5008503455 @default.
• W4313559631 hasAuthorship W4313559631A5011414875 @default.
• W4313559631 hasAuthorship W4313559631A5014788787 @default.
• W4313559631 hasAuthorship W4313559631A5029554092 @default.
• W4313559631 hasAuthorship W4313559631A5031148071 @default.
• W4313559631 hasAuthorship W4313559631A5035987097 @default.
• W4313559631 hasAuthorship W4313559631A5048460948 @default.
• W4313559631 hasAuthorship W4313559631A5050897246 @default.
• W4313559631 hasAuthorship W4313559631A5057731725 @default.
• W4313559631 hasAuthorship W4313559631A5066499069 @default.
• W4313559631 hasAuthorship W4313559631A5068905678 @default.
• W4313559631 hasAuthorship W4313559631A5072413175 @default.
• W4313559631 hasAuthorship W4313559631A5081007211 @default.
• W4313559631 hasAuthorship W4313559631A5082072905 @default.
• W4313559631 hasAuthorship W4313559631A5089944976 @default.
• W4313559631 hasBestOaLocation W43135596311 @default.
• W4313559631 hasConcept C119060515 @default.
• W4313559631 hasConcept C126322002 @default.
• W4313559631 hasConcept C2776656118 @default.
• W4313559631 hasConcept C2779134260 @default.
• W4313559631 hasConcept C2779483572 @default.
• W4313559631 hasConcept C2984863031 @default.
• W4313559631 hasConcept C44249647 @default.
• W4313559631 hasConcept C58471807 @default.
• W4313559631 hasConcept C71924100 @default.

• next